Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities

Jehad Alzahraia,b,1, Tabinda Hussainc,1, David Simaron, Riya Palchaudhurib, Mohamed Abdel-Mohsenf,
Suzanne M. Crowea,d, George W. Mbogo a,1, Clovis S. Palmerabg,⁎

1 Authors contributed equally.
⁎Corresponding author.
E-mail address: clovis.palmer@burnet.edu.au (C.S. Palmer).

Article history:
Received 29 March 2019
Received in revised form 7 July 2019
Accepted 9 July 2019
Available online 18 July 2019

Keywords:
Inflammatory bowel disease
Inflammation
HIV cure
Macrophage metabolism
Immunometabolism, microbiome

ABSTRACT

The gastrointestinal mucosa is critical for maintaining the integrity and functions of the gut. Disruption of this barrier is a hallmark and a risk factor for many intestinal and chronic inflammatory diseases. Inflammatory bowel disease (IBD) and HIV infection are characterized by microbial translocation and systemic inflammation. Despite the clinical overlaps between HIV and IBD, significant differences exist such as the severity of gut damage and mechanisms of immune cell homeostasis. Studies have supported the role of metabolic activation of immune cells in promoting chronic inflammation in HIV and IBD. This inflammatory response persists in HIV+ persons even after long-term virologic suppression by antiretroviral therapy (ART). Here, we review gut dysfunction and microbiota changes during HIV infection and IBD, and discuss how this may induce metabolic reprogramming of monocytes, macrophages and T cells to impact disease outcomes. Drawing from parallels with IBD, we highlight how factors such as lipopolysaccharides, residual viral replication, and extracellular vesicles activate biochemical pathways that regulate immunometabolic processes essential for HIV persistence and non-AIDS metabolic comorbidities. This review highlights new mechanisms and support for the use of immunometabolic-based therapeutics towards HIV remission/cure, and treatment of metabolic diseases.

This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1. Introduction ........................................................................................................................................ 523
   1.1. Microbial dysbiosis “the Achilles heel” of “leaky gut” associated syndromes ........................................ 523
   1.2. Short chain fatty acid: pathways to targeted therapies ......................................................................... 523
   1.3. Monocyte driven inflammation underlies IBD pathology and associated age-related comorbidities .... 524
   1.4. Microbial translocation in health and disease: Insights into gastrointestinal and systemic inflammation ......................................................................................................................... 524
   1.5. Mechanisms of gut barrier breach ........................................................................................................ 525
   1.6. The role of Th17 cells in HIV infection and IBD. .................................................................................... 525
   1.7. Microbial effectors of “leaky gut” pathogenesis: the role of LPS-mediated signaling on monocyte activation and systemic inflammation ................................................................. 525
   1.8. Metabolic reprogramming regulates monocyte/macrophage activation and inflammation ................ 525
       1.8.1. Regulators of metabolic reprogramming .................................................................................. 525
       1.8.2. Metabolic reprogramming in IBD and HIV infection .................................................................. 526
       1.8.3. LPS reprograms monocyte and macrophage metabolism from oxphos towards glycolysis ........ 527
   1.9. Other factors driving metabolic reprogramming and inflammation in immune cells in HIV+ persons .......................................................... 527
   1.10. Immunometabolism offers promising opportunities towards HIV remission and cure. ......................... 527

⁎ Corresponding author.
E-mail address: clovis.palmer@burnet.edu.au (C.S. Palmer).

1 Authors contributed equally.

https://doi.org/10.1016/j.ebiom.2019.07.027
2352-3964/This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Approximately 37 million people are currently living with HIV infection globally, with about 21.7 million receiving antiretroviral treatment (ART) [1]. The use of ART has greatly reduced the incidence of AIDS-related morbidity and mortality with most HIV-infected individuals having nearly normal life expectancy [2]. However, ART does not eradicate HIV [3]. People living with HIV, even after suppressive ART, experience high incidence of non-AIDS associated comorbidities, including cardiovascular disease (CVD), frailty, and osteoporosis, liver and kidney disease, and non-AIDS-associated cancers [4–7]. Chronic immune activation and inflammation have been identified as the most common risk factor underlying these co-morbidities [8–10]. Chronic inflammation during suppressive ART is multi-factorial, with microbial translocation through the gut barrier being a significant contributor [7].

The gastrointestinal (GI) tract is the major site of HIV replication and persistence of the HIV reservoir [11,12], with early events following HIV infection resulting in rapid loss of GI mucosal integrity. These alterations lead to an increase in GI permeability and translocation of microbial products from the gut lumen across the damaged mucosa into the circulation leading to chronic systemic inflammation [7]. The significance of gut microbiota and gut integrity in HIV pathogenesis is underscored by clinical trials showing that daily probiotic supplementation to ART-naive HIV+ persons, decreased immune cell activation, lowered levels of proinflammatory markers [13], and reduced microbial translocation [14]. The benefits were recapitulated in ART-suppressed HIV+ persons [15], highlighting the potential beneficial effects of some probiotic species in modulating GI disorders and impacting HIV disease progression. However, a lack of understanding of the underlying molecular and biochemical pathways mediating chronic immune activation and inflammation in HIV+ persons precludes the discovery of novel and more specific therapeutics to eradicate gut-resident HIV-reservoir cells, and prevent non-AIDS associated comorbidities.

The causes for the “leaky gut syndrome” are multifactorial and in this review, we will showcase how lessons learnt from HIV and inflammatory bowel diseases (IBD) can enable greater understanding of etiology and mechanisms of gut dysfunction in each condition. We will also highlight how IBD itself is a potentially serious non-modifiable risk factor for the development of non-AIDS co-morbidities.

1.1. Microbial dysbiosis “the Achilles heel” of “leaky gut” associated syndromes

The complex intestinal ecosystem is comprised of trillions of bacteria performing crucial homeostatic functions [16]. Several lines of evidence have implicated alterations in the intestinal microbiota (dysbiosis) to infectious diseases and metabolic disorders such as HIV infection, obesity, and CVD, elegantly reviewed by Godfrey and colleagues [7]. In the context of HIV, disease progression is strongly associated with changes in the enteric microbiota and systemic abnormalities, a concept described as a “two-way street” [17]. This vicious pathological cycle exacerbates HIV-associated immune activation and inflammation [18]. Based on observations regarding the beneficial effects of restoring gut microbial homeostasis and immune functions in metabolic disorders and HIV, deciphering the precise molecular mechanisms is paramount.

The composition of gut bacteria varies significantly between HIV+ ART-suppressed, and HIV uninfected persons [19]. However, there is no consensus about specific bacterial diversity at genus or species level [19]. In clinical studies, several factors could act as confounders, affecting the reliability of microbiome data including: sampling differences such as mucosal versus luminal, lack of standardization in sample collection and analysis, and biological effect of diet, medications and geographic location [19]. Additionally, ART regimens, MSM (men who have sex with men) versus heterosexual males [20], level of immune activation and CD4 T cell recovery status on ART [21], as well as the use of Truvada (emtricitabine, tenofovir disoproxil fumarate) as HIV pre-exposure prophylaxis (PreP) in HIV-negative persons [22] have profound effects on the gut microbiome. Notwithstanding, an increase in members of the genus Prevotella in HIV+ versus HIV-negative healthy controls has been reported [18,21,23]. At the biochemical level, enrichment of Lactobacillus in HIV+ persons may result in catabolism of tryptophan to indole-3-aldehyde by way of the tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase (IDO) [24]. This could create a vicious cycle linking dysbiosis with activation of the kynurenine/IDO pathway and pro-inflammatory cytokine production. It could further lead to a loss of Th17 cells from the gut mucosa, further compromising the integrity of the GI tract [25]. A similar increase in Proteobacteria [26] and Actinobacteria and a decrease in Firmicutes has been reported in IBD, as well as an increased expression of IDO in intestinal biopsies [27]. Interestingly, microbial dysbiosis did not promote disease progression in simian immunodeficiency virus (SIV)-infected macaques [28], highlighting the importance of being aware of model-specific outcomes when trying to understand the mechanism of diseases in humans.

Immune cells themselves also regulate tryptophan biogenesis. In this regard, LPS-conditioned dendritic cells induce IDO isoforms that preferentially induce NF-κB inflammatory pathway, which may contribute to an immunosuppressive gut environment [29,30]. Similar immunosuppressive and tolerogenic response has been described in macrophages over-expressing IDO via Interleukin-32 (IL-32) and Toll-like receptor 9 (TLR9) stimulation [31,32].

1.2. Short chain fatty acid: pathways to targeted therapies

Dysbiosis is characterized by an increase in the number of pathogenic microbes relative to the useful commensal microflora [33]. These changes contribute to diminished levels of anti-inflammatory short chain fatty acids (SCFAs) such as butyrate. Such SCFAs are produced by fermentation of dietary fiber by commensal bacteria contributing to improving gut homeostasis and barrier integrity. SCFAs can restore gut barrier function [34], and may explain some of the protective effects of probiotics and prebiotics in several inflammatory conditions including HIV [35–37]. Seminal work by Arpaia et al. has demonstrated the role of microbial metabolites in restoring intestinal anti-inflammatory regulatory T cells (Treg cells) populations in mouse models [38]. Butyrate promoted gut-associated anti-inflammatory Tregs, while propionate led to their de novo production through histone deacetylase (HDAC) inhibition [38]. In IBD, SCFAs are significantly reduced and supplementation with Lactobacillus strains improved intestinal inflammation and gut barrier function [39]. Similarly, HIV+ persons on ART with increased gut Lactobacilli showed reduced microbial
translocation and increased CD4 T cells [40]. It remains to be established how exactly gut microbiota and the associated metabolites mechanistically influence the intestinal barrier and the consequent inflammation in distinctive diseases including IBD and HIV. However, SCFAs like butyrate, can be transported into immune cells to fuel mitochondrial metabolism and ATP synthesis, in order to maintain an oxidative anti-inflammatory state. In the case of probiotic supplementation, butyrate may dampen inflammation by suppressing glycolysis in immune cells (discussed below), while promoting synthesis of antimicrobial molecules by macrophages (Fig. 1A), as previously reviewed [7,41].

1.3. Monocyte driven inflammation underlies HIV pathology and associated age-related comorbidities

During HIV infection, there is persistent low-level inflammation and immune activation that leads to disease progression and the risk of serious non-AIDS comorbidities [42]. Monocyte activation is associated with all-cause risk of mortality in HIV+ persons on ART. Several works have shown that HIV infection is associated with monocytes and macrophages exhibiting Warburg-like features [43]. This Warburg effect is characterized by increased glycolysis and lactate production in the presence of physiological concentrations of oxygen (aerobic glycolysis). It also corresponds to a situation where glycolytic enzymes and substrates regulate immune cell activation and inflammatory states, beyond their metabolic roles [44]. This may also represent the metabolic basis of immunosenescence and immune cell aging [45]. It could also contribute to the development of non-AIDS co-morbidities such as CVD, HIV-associated neurocognitive disorder (HAND), osteoporosis and frailty [6,46–51]. This immune activation and inflammatory state is characterized by increased circulating levels of IL-6, soluble CD14 (sCD14) and sCD163 even after suppressive ART [10].

1.4. Microbial translocation in health and disease: Insights into gastrointestinal and systemic inflammation

Gut barrier dysfunction increases bacterial extracellular vesicles (EV)-associated LPS and other LPS products in IBD and HIV+ persons [52,53]. This scenario reveals a complex interplay of factors in both IBD and HIV that would potentiate and aggravate the pathogenesis of both diseases. Thus, HIV-mediated immune deficiency could compromise the host’s ability to clear LPS in IBD, whereas pre-existing IBD could heighten inflammation and recruitment of HIV target cells, in addition to the other pleiotropic effects of microbial translocation in both settings.

Besides LPS products increased fungal colonization of the gut during HIV infection represents another significant contributor to inflammation in HIV. Plasma levels of the fungal polysaccharide (1 → 3)-β-D-glucan (β-DG) are elevated in long-term ART treated HIV+ persons and correlates with gut damage, bacterial translocation, immune activation, and inflammation [54]. Monocytes exposed to fungal β-glucans undergo metabolic reprogramming, leading to ‘trained immunity’ characterized by an enhanced proinflammatory status upon secondary stimulation [55]. Thus β-DG presents an important immunometabolic regulator in HIV and a potential therapeutic target to limit development of non-AIDS associated comorbidities [54].

1.5. Mechanisms of gut barrier breach

There is evidence that HIV infection breaches the gut barrier in a way similar to IBD. Indeed expression of junctional complex proteins, claudin 1, cadherin, and Zonula occludens protein 1 (ZO-1), in gut was significantly downregulated in gut biopsies from HIV+ persons with incomplete CD4 T cell recovery [56]. In these persons, increased infiltration of CD8 T cells, rapid depletion of CD4 T cells, oxidative stress and

Fig. 1. Model showing potential inflammatory and immunometabolic consequences of gut barrier dysfunction in HIV infection. In HIV-negative persons the presence of Firmicutes in the gut enhances fermentation of dietary fiber to short chain fatty acids which have anti-inflammatory functions as well as promoting break down of glucose and fatty acid via oxidative metabolism (B). Damaged epithelial cells facilitate translocation of bacterial and fungal products across the intestinal lumen through the epithelial cells and into the blood stream. ROS and the inflammatory environment may cause low levels of HIV transcription and release of pro-glycolytic/immunometabolic extracellular vesicles (EVs) by metabolically active CD4 T cells (B). The activation of monocytes/macrophages may increase the demand of glucose facilitated by increased Glucose Transporter 1 (Glut1) expression. High glycolytic metabolism by recruited monocytes and pro-inflammatory M1-like macrophages results in increased production of cytokines such as IL-6 and TNF which contribute to the chronic inflammation observed in HIV+ people. Figures designed using image stocks from nice-consultants.com.
release of TNF, IL-2 and IL-4 was associated with GI damage and intestinal permeability through disruption of tight junctions [57,58] and enterocyte apoptosis [59]. It remains unclear how HIV itself may participate in gut barrier dysfunction and immune cell trafficking in inflamed gut submucosa. However, Kamogone and colleagues reported that in the brain, exposure of epithelial cells to HIV envelope glycoprotein gp120 disrupted the tight junctions and enhanced monocyte transmigration across the blood-brain barrier [60]. The common ontology of epithelial cells despite their anatomical location could allow for a possible extrapolation of this phenomenon to mucosal tight junctions during HIV infection.

Whilst HIV and IBD share some similarities, differences exist such as the area of the intestine affected and the degree to which disruption is manifested. For example, Crohn’s disease and ulcerative colitis have profound damage and ulceration. In contrast, studies in ART-naive HIV+ persons, with late-stage HIV infection showed only mild-to-moderate enteritis or colitis in the duodenum and jejunum. Further, CD4 T cell loss was more pronounced in the small (duodenum, jejunum, and ileum) versus large (colon) intestine of untreated HIV+ persons [61].

1.6. The role of Th17 cells in HIV infection and IBD

A balance between the effector and regulatory functions of Th17 and Tregs is important in maintaining gut barrier integrity and functions [62]. IL-17, secreted by Th17 cells increases the expression of tight junction proteins claudin-1 and claudin-2 essential for maintaining gut integrity and inhibiting bacterial translocation [63]. Conversely, separate studies showed that Th17 cells are severely depleted and functionally impaired during HIV infection thereby triggering mucosal barrier damage and microbial translocation [64]. This could be due to the fact that a significant proportion of Th17 cells express CCR5, a HIV co-receptor [65]. It should be noted that the depletion of Th17 cells is common in both HIV infection and IBD, although in the latter there is a differential upregulation of cytokine secretion (IL-17, IL-22) [66]. At a glance, Th17 effector functions appear to be more important in regulating HIV-mediated gut barrier dysfunction than in IBD with both diseases acting as independent predisposing or aggravating risk factors. Therefore, exploration of the role of Th17 dynamics in the context of HIV infection, IBD and gastrointestinal repair would yield interesting pathophysiologic insights upon which novel therapies may be developed to improve gut functions.

1.7. Microbial effectors of “Leaky gut” pathogenesis: the role of LPS-mediated signaling on monocyte activation and systemic inflammation

LPS is an integral component of the bacterial structure released upon bacterial lysis and death [67] and can activate monocytes and macrophages by binding to circulating plasma lipopolysaccharide binding protein (LBP), which initiates a metabolic signaling cascade to produce inflammatory molecules (Fig. 2).

Notably, gut resident macrophages can exhibit an anergic phenotype to inflammatory cues as they do not express CD14 co-receptor for LPS and may have impaired production of inflammatory cytokines. This phenotype is ideal for an environment with constant exposure to microbial flora as previously reviewed [68]. However, during gut barrier dysfunction as observed during HIV infection and IBD, this inflammatory landscape changes considerably due to the recruitment and accumulation of activated blood monocytes in the lamina propria [68] and as observed during HIV infection and IBD [61,69].

In IBD there is increased recruitment of blood monocytes to the gut, which is associated with an upregulation of monocyte-targeted chemokines (MCP-1, CCL2, CCL4) by endothelial cells. This leads to migration of monocytes to the inflamed intestinal tissue amplifying the inflammatory cascade. Furthermore, upregulation of various ligands including P-selectin glycoprotein ligand-1 (PSLG-1), P-selectin, CD34, and VCAM-1 has been observed, and could promote monocyte extravasation into the ileal mucosa [70,71]. Monocyte-derived macrophages are more reactive compared to their gut resident counterparts and have increased secretion of pro-inflammatory cytokines, such as TNF, IL-1 and IL-6, IL-23 [69,72]. Metabolically active monocytes such as those expressing high levels of glucose transporter 1 (Glut1) [73] may be preferentially recruited to the adipose tissues and gut of HIV+ persons creating a vicious inflammatory cycle [74] (Fig. 1B).

Kamada et al. found a unique highly pro-inflammatory intestinal macrophage subset in Crohn’s disease patients [69]. Despite the dogma that intestinal macrophages are devoid of CD14 receptor, this distinct subset expresses both typical macrophage (CD14, CD33, CD68) and dendritic cell markers (CD205, CD209) [69]. These cells also secrete pro-inflammatory cytokines, such as IL-23, IL-6 and TNF. The increase in IL-23 shifts the balance in favor of IFN-γ secretion from lamina propria mononuclear cells (LPMCs) instead of IL-17, which further heightens abnormal macrophage differentiation and intestinal inflammation in individuals with Crohn’s disease [69]. IL-23 has also been implicated as the central regulator for the expansion of Th17 cells expressing CD4 that secrete pro-inflammatory cytokines like IL-17α, IL-22, IFN-γ. The increase in Th17 cells in individuals with IBD is induced by IL-23, which is secreted by lamina propria macrophages [74,75]. In contrast to IBD, HIV is characterized by a pathological loss of Th17 cells and their full function is not achieved even with virologic suppression on ART.

The expression profile and phenotype of intestinal macrophages are similar in HIV infection and IBD, implying that both diseases could have overlapping pathophysiological changes (Table 1).

In the context of HIV, Cassol and colleagues observed an increased secretion of IL-18, IFN-γ, CCL2, TNF receptor associated factor (TRAF6) and IL-12Rβ1 as well as an increase in CD14 macrophages in colons of HIV+ persons [61]. These data are similar to those from Kamada et al. in persons with Crohn’s disease [69]. Similarly, an increased mucosal enrichment of macrophages was observed in the jejunal lamina propria of primary HIV+ patients compared to HIV-uninfected controls. This increased trafficking was associated with elevated levels of integrin (57 on monocytes, a gut-homing molecule that supports monocyte gut infiltration [90].

1.8. Metabolic reprogramming regulates monocyte/macrophage activation and inflammation

1.8.1. Regulators of metabolic reprogramming

All immune cells utilize glucose in order to produce energy to mount an effective immune response against pathogens [107–109]. Glucose is metabolized via two major pathways: oxidative phosphorylation (oxphos), which takes place in the mitochondria to produce maximal amount of ATP, and glycolysis, which occurs in the cytosol and produces less ATP. Aerobic glycolysis produces precursors of protein, lipid, and nucleotide synthesis that are needed by activated and rapidly proliferating cells [110,111].

The key event that marks metabolic reprogramming of LPS-stimulated macrophages is the overexpression of Glut1, the major glucose transporter that supports an increase in glycolytic flux [112]. Freemerman and others have shown that macrophages with increased expression of Glut1 secrete higher levels of TNF, IL-6, and CXCL2 representing a hyperinflammatory state [113]. LPS-mediated signaling in macrophages initiates a metabolic switch from oxphos to glycolysis, similar to the ‘Warburg effect’ [114], which has been shown to be dependent on NAD+ salvage pathway to maintain NAD+ pools [115]. Like activated monocytes, macrophages of the M1-like pro-inflammatory phenotype have a glycolytic signature, while M2-like macrophages, responsible for producing anti-inflammatory cytokines, rely mostly on oxidative metabolism and beta oxidation of fatty acids to generate ATP [107,116]. Blocking oxidative metabolism has been successful at abrogating the M2-like phenotype and increasing the number
of M1-like macrophages in bone marrow derived macrophages and murine models [116,117]. Since the metabolic status of macrophages intricately connects their inflammatory and developmental status, it is conceivable that new macrophage nomenclature may be considered based on their biochemical imprints to better distinguish their functional phenotypes.

Glycolytic influx is also essential for maintaining morphological changes in macrophages that are required for phagocytosis upon LPS stimulation. Venter et al. have shown that a low level of extracellular glucose was required for remodeling of cytoskeleton in M1-like macrophages [118]. These studies suggest that metabolic reprogramming of macrophages is a key event that has both metabolic and non-metabolic consequences on macrophage function.

1.8.2. Metabolic reprogramming in IBD and HIV infection

In a murine model of IBD, a Glut1 conditional knockout in CD4 T cells led to a reduction in disease progression with a less pro-inflammatory cytokine profile. Since Glut1 deletion caused failure of immune cells to increase glucose metabolism, this could have led to abrogation of the inflammatory response [119]. Recent studies reviewed by Venegas et al. have found that metabolism of butyrate, a SCFA, is impaired in inflamed mucosa of IBD patients [120]. Defects in butyrate oxidation could be related to multiple mechanisms, with suggestions that upregulation of Glut1 causes a switch from butyrate to glucose oxidation. This leads to impairment of cellular homeostasis and suppression of the anti-growth action of butyrate. Such a scenario would cause damage to colonocytes and worsen the pathology of IBD by supporting glycolysis and increasing inflammation [121].

The activation of monocytes during HIV infection is accompanied by increased aerobic glycolysis, mediated by increased cell surface expression of Glut1, elevated glucose uptake, and enhanced lactate production even in the presence of sufficient oxygen. High glycolytic metabolism by monocytes is essential for the production of pro-inflammatory cytokines such as IL-6 and TNF [122,123]. Therefore, expression of metabolic regulators such as Glut1 on monocytes may be explored as a potential marker of immune activation and inflammation in people with chronic inflammatory diseases such as IBD and HIV. This is supported by studies...
Disruption of tight junctions, Villous atrophy | YES [76,77] | YES [78,79]
Microbial translocation | ↑LBP, ↑LPS, ↑EndoCaB | ↑LBP, ↑EndoCaB, O LPS [80–82] [83,84]
Inflammation activation | YES [85,86] | YES [87,88]
Increased | YES [82,89,90] | YES [72,91,92]

**Table 1** Comparison of immunopathological changes in HIV and inflammatory bowel disease.

| Marker | HIV | IBD |
|--------|-----|-----|
| Disruption of tight junctions, Villous atrophy | YES [76,77] | YES [78,79] |
| Microbial translocation | ↑LBP, ↑LPS, ↑EndoCaB | ↑LBP, ↑EndoCaB, O LPS [80–82] [83,84] |
| Inflammation activation | YES [85,86] | YES [87,88] |
| Increased | YES [82,89,90] | YES [72,91,92] |

Comparison of immunopathological changes in HIV and inflammatory bowel disease.

1.8.3. LPS reprograms monocyte and macrophage metabolism from oxphos towards glycolysis

Higher levels of L-lactate secretion are observed in activated monocytes in vitro by LPS and IFN–γ. In activated monocytes, the amount of L-lactate secreted due to glycolytic metabolism is higher in activated monocytes than in other monocyte subpopulations, suggesting that intermediate monocyte inflammatory responses are driven by glycolytic metabolism [112]. Therefore, we propose a model in which gut microbial translocation results in increased levels of bacterial products such as LPS in the blood. In turn, LPS induces activation of monocytes and macrophages mediated by increases in Glut1 expression and glycolysis, thus promoting pro-inflammatory cytokine synthesis critical for the development of age-associated comorbidities in HIV+ persons [122,125]. Important in this model is the imbalance of good and bad bacteria such as reduced *Firmicutes*, essential for the production of anti-inflammatory SCFAs, which helps to maintain gut integrity (Fig. 1A).

Modulation of glucose, lipid and glutamine metabolism are emerging as promising therapeutic approaches to alleviate the impact of inflammatory diseases, such as HIV and IBD [123,126,127]. The increase in metabolism is a characteristic feature of monocytes during a rapid activation period that is regulated at least in part by the PI3K/Akt/mTOR axis and glucose-metabolizing enzymes such as glutaminase. Therefore, normalization of overactive metabolic activity of monocytes and macrophages by therapeutic targeting of these pathways presents potential to treat existing inflammatory conditions or develop prophylactic treatments for patients at higher risk of leaky gut syndrome and gut inflammation (Fig. 2).

Of note, not all data support this hypothesis. One study found human peripheral blood monocyte-derived macrophages activated with LPS did not undergo metabolic reprogramming towards glycolysis, but instead exhibited an oxidative phenotype. By contrast, mouse bone marrow-derived macrophages challenged with LPS showed increased glycolysis and reduced oxidative phosphorylation. It may be argued that human cells and murine cells have significant biological differences [128]. Regardless, it emphasizes that caution should be taken when interpreting metabolic data from animal models, or different cell types due to intrinsic physiological differences.

1.9. Other factors driving metabolic reprogramming and inflammation in immune cells in HIV+ persons

Besides LPS, other factors may induce monocyte and macrophage activation and metabolic reprogramming. HIV proteins such as viral protein-τ (vpr) produced during residual replication, may induce metabolic switch in HIV-1 infected macrophages from oxphos towards glycolysis through hypoxia-inducible factor 1 (HIF-1α) and peroxisome proliferator-activated receptor gamma (PPARγ)-dependent mechanisms. These metabolic effects may be manifested by pronounced glucose uptake and elevation of critical glycolytic enzymes in infected macrophages [129] and dysregulated systemic lipid metabolism [130]. Metabolic activation of macrophages by HIV may cause accumulation of α-ketoglutarate and glutamine, suggesting a compensatory mechanism to fuel the tricarboxylic acid cycle (TCA) cycle and ATP production via oxphos [108].

Type 1 and II interferons within the microenvironment may impact activation and glycolysis in macrophages [131,132]. Indeed, IFN–γ through activation of the JAK (Janus tyrosine kinase)-STAT-1 (Signal Transducer and Activator of Transcription 1) induces a robust glycolytic response while reducing oxphos in M1-like pro-inflammatory macrophages [132].

Apart from soluble factors, extracellular vesicles (EVs) have been shown to be potential key players in HIV disease pathogenesis. HIV-infected CD4 T cells release pro-glycolytic EVs, which induce cytokine secretion from bystander lymphocytes and macrophages [97]. Thus the coordinated actions of immune cell metabolic reprogramming and EVs may participate in inflammatory responses that underlie immunometabolic-related sequelae in HIV infection [97].

In ART-treated HIV+ persons, the treatment regimen itself may also affect immune cellular metabolism and function due to mitochondrial impairment. In fact CD4 T cells exposed to integrase inhibitors dolutegravir or elvitegravir exhibit reduced functions [96]. Finally, it has been shown that in HIV+ persons opportunistic pathogens, such as cytomegalovirus (CMV), can disrupt epithelial junctions, which significantly impairs gut barrier and potentiate chronic inflammation [133].

1.10. Immunometabolism offers promising opportunities towards HIV remission and cure

Compelling evidence shows that immune cell metabolism underlies mechanisms essential for HIV persistence and inflammation in ART-treated HIV+ persons. A specific plasma metabolic/metabolic signature is associated with the natural control of HIV infection. Compared to HIV persistent controllers, patients who lost their ability to naturally control HIV without ART have a plasma metabolomic profile enriched with glycolytic intermediates implying disturbances in oxidative metabolism and mitochondrial functions [134]. Systemic lipid dysregulation is also associated with HIV-specific T–cell responses that are important for viral control in untreated HIV infection [134].

Similar immune cellular metabolic changes are associated with CD4 T cell activation, HIV replication and HIV reservoir seeding [97,99,135,136,142]. Indeed, ROS-mediated HIF-1α signaling induces metabolic reprogramming and residual HIV replication in HIV-infected...
CD4 T cells. Further, extracellular vesicle release from metabolically-stressed CD4 T cells may release their cargo to uninfected recipient macrophages and T cells to induce a glycolytic phenotype that increases HIV infectivity [97,99]. Such immune cell metabolic dysregulation is also linked to T cell exhaustion and reduced functionality [137].

Promising strategies to rewire or re-polarize cells towards their normal metabolic status include use of mTOR inhibitors (e.g rapamycin clinical trialNCT02440789) [123], and AMPK activators (e.g metformin) [138] to regain immune functions [139]. mTOR inhibitors may also suppress reactivation of HIV, a strategy called “lock and block” [140,141] or reduce proliferation of HIV reservoir cells to “starve the reservoir” [123]. Other emerging metabolic targets include Glutaminase (GLS1 and GLS2) that catalyze the conversion of glutamine to glutamate, and glutamate dehydrogenase that converts glutamate to α-ketoglutarate [108,142]. This anaplerotic reaction drives production of mitochondrial ATP as a compensatory energy-producing pathway in glycolytic T cells and macrophages. Indeed, glutamate/glutamate represents a major energy source for surviving HIV-infected macrophages, and inhibiting glutaminase activity with bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES) or benzylserine caused death of these latently infected cells [100].

Such interventions may also be adaptable to repolarize pro-inflammatory glycolytic-M1 macrophages towards an anti-oxidative M2 phenotype as promising therapies to treat and prevent metabolic-mediated non-AIDS co-morbidities.

2. Conclusion

Here we bring together evidence to support a model by which increased intestinal permeability and microbial translocation instigate a peripheral pro-glycolytic inflammatory environment in both HIV and IBD. These diseases share several commonalities, of which disruption of the intestinal tight junction, inflammation and immune cellular metabolic reprogramming are hallmarks. However, while these similarities exist, there are unique differences in terms of the genera and species of the microbial population, and mechanisms of immune cell homeostasis, in the gut.

Compromised gut barrier and metabolic remodeling of immune cells may also play a central role in the pathophysiology of obesity, cancer and aging diseases related to, or independent of HIV infection [67,74,73]. Beyond implication for HIV cure [100,125,126] and treating non-AIDS non-communicable diseases.

Distinct metabolic features include: (1) increased glutamine/glutamate as a major energy substrate and (2) altered amino acid metabolism, including glutamine and branched chain amino acids.

Outstanding questions

There are significant gaps in our knowledge on how fundamental biochemical processes in gut endothelial and immune cells are affected in HIV infection and how this influences reservoir persistence in the gut. To bridge this knowledge gap, it is important to decipher whether gut barrier dysfunction and its inflammatory consequences in HIV infection are the results of perturbed cellular mechanisms or whether altered processes are simply the manifestation of infection. How does pre-existence of IBD or HIV affect the risk of acquisition of the other and clinical progression? A better fundamental understanding of these aspects will improve diagnosis and long-term management of patients.

Search strategy and selection criteria

Content for this review were obtained through PubMed search and Google Scholar using the search terms “HIV leaky gut” “IBD leaky gut” “macrophage metabolism” “monocyte metabolism” “Immunometabolism IBD” “HIV inflammation” “IBD inflammation” “HIV immunometabolism” “Metabolism HIV cure”. To obtain up-to-date scientific evidence we placed preferences for articles published between 2014 and 2019, except where seminal articles were relevant.

Authors’ contribution

C.S.P. conceptualized the review, organized, wrote the manuscripts, formulated models, and designed the images. J.A., T.H., R.P., and C.G.W. wrote the manuscript. D.S and S.M.C provided critical analysis, provided content and edited the manuscript. M.A-M edited the manuscript and provided critical insights.

Declaration of Competing Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

CSP is funded by the Australian Centre for HIV and Hepatitis Virology Research (ACH2) and receives unrestricted funding from Merck Sharp & Dohme. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The authors also thank nice-consultants.com for expertise assistance on graphic design of figures. C.S.P is grateful to Dr Darren Lockie who provided donations to support his research lab.

References

[1] Feyissa GT, Lockwood C, Wolde M, Muon Z. Reducing HIV-related stigma and discrimination in healthcare settings: a systematic review of quantitative evidence. PLoS One 2019;14(1):e0211298.
[2] Legarth RA, Ahloost MC, Kroongb C, Larsen CS, Pedersen C, Pedersen G, et al. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide population-based cohort study. J Acquir Immune Defic Syndr 2016;71(2):213–8.
[3] Deeks SG, Lewin SR, Ross AL, Anawarwach J, Benikane M, Cannon P, et al. International AIDS society global scientific strategy: towards an HIV cure 2016. Nat Med 2016;22(8):839–50.
[4] Heps AC, Angelovich TA, Jaworowski A, Mills J, Landay AL, Crieve SM. HIV infection and aging of the innate immune system. Sex Health 2011;8(4):453–64.
[5] Yeoh HL, Cheng A, Palmer C, Crieve SM, Hoy JJ. Frailty in men living with HIV: a cross-sectional comparison of three frailty instruments. Antivir Ther 2018;23(2):117–27.
[6] Yeoh HL, Cheng AC, Cherry CL, Weir JM, Melide PJ, Hoy JJ, et al. Immunometabolic and Lipidomic markers associated with the frailty index and quality of life in aging HIV + men on antiretroviral therapy. EBioMedicine 2017;22:112–21.
[7] Godfrey C, Brenner A, Alba D, Apovian C, Koethe JR, Koliwad S, et al. Obesity and fat metabolism in HIV-infected individuals: Immunopathogenic mechanisms and clinical implications. J Infect Dis 2019;200(3):420–31.
[8] Borges AH, O’Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus J, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. J Infect Dis 2016;214(3):408–16.
[9] Grund B, Baker JV, Deeks SG, Wollson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of Interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One 2016;11(5):e0155100.
[10] Anzinger J, Butterfield TR, Angelovich TA, Crieve SM, Palmer CS. Monocytes as regulators of inflammation and HIV-related comorbidities in cART. J Immunol Res 2014;2014:569819.
[11] Yoder AC, Guo R, Dillon SM, Phang T, Lee LJ, Harper MS, et al. The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteria. PLoS Pathog 2017;13(2):e1006226.
[12] Wong JK, Yuld SA. Tissue reservoirs of HIV. Curr Opin HIV AIDS 2016;11(4):362–70.
[13] Gori A, Rizzardini G, Varst Land B, Amor KB, van Schaik J, Torti C, et al. Specific probiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPIA” pilot randomized trial. Mucosal Immunol 2011;4(5):554–63.
[14] Villar-Garcia J, Hernandez JJ, Guerri-Fernandez R, Gonzalez A, Lerma E, Guelar A, et al. Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial. J Acquir Immune Defic Syndr 2015;68(3):256–63.
[15] Delortore G, Ceccarelli G, Giustini N, Serafini S, Calantone N, De Girolamo G, et al. Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the “Probio-HIV” clinical trial. PLoS One 2015;10(9):e0137200.
[16] Roos MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016;16(6):341–52.
Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two-way street. AIDS 2016;30(18):2737–51.

Blome CV, Lee EJ, Austin CL, Cella S, Siwee B, et al. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. Mucosal Immunol 2016;9(1):24–37.

Gottenberg JB, Paer JM, Lunzano VD, HS. HIV-associated changes in the enteric microflora: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis 2017;30(1):31–43.

Armstrong AJ, Shaffer M, Nusbaumer GM, Grisemer C, Fiorillo S, Schneider JM, et al. An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. Microbiomes 2015;3:198.

Lu W, Feng Y, Jing F, Han Y, Lyn Y, Liu F, et al. Association between gut microbiota and CD4 recovery in HIV-1 infected patients. Front Microbiol 2018;9:1841.

Dube MP, Park SY, Ross H, Love TMT, Morris SR, Lee HY. Daily HIV pre-exposure prophylaxis (PrEP) reduces tenofovir disoproxil fumarate-reduced Streptococcus and increased Erysipelothrix in rectal microbiota. Sci Rep 2018;8(1):15122.

Mutha EA, Keshavarzian A, Lusardo J, Swanson G, Siwee B, Forsyth C, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog 2014;10(2):e1003829.

Vyboh K, Jenabian MA, Mehrjah V, Routy JP. HIV and the gut microbiome, partners in crime: breaking the vicious cycle to unear new therapeutic targets. J Immunol Res 2015;2015:84127.

Vujkovic-Cvijin I, Swanson LA, Chu SN, Ortiz AM, Appay V. Harnessing the induction of CD8(+) T-cell responses against intracellular pathogens in SIV-infected macaques. Cell Rep 2015;13(8):1589.

Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, et al. Overexpression of gamma-H2A.X in CD14(+) intestinal macrophages contributes to the pathogenesis of Crohn disease via contributes to the pathogenesis of Crohn disease. Cell Rep 2016;30(7):991.

Inoue T, Tsuzuki Y, Matsuzaki K, Matsunaga H, Miyazaki J, Hokari R, et al. Blockade of NK cell activation by normal bacteria and bacterial products: implications for allogeneic immune activation during HIV infection. J Immunol 2013;191(5):2164–72.

Fukui SM, Piggott DA, Erdmann LA. HIV and the gut microbiota, partners in two-way street. AIDS 2016;30(18):2737–51.

Shan Z, Clish CB, Hua S, Scott JM, Hanna DB, Burk RD, et al. Gut microbiota-derived fitC-peptide reduces coreceptor and CD4-activated T-cell function in HIV-1-infected adults on stable antiretroviral therapy. PLoS One 2016;11(2):e0149133.

Shan Z, Clish CB, Hua S, Scott JM, Hanna DB, Berk RD, et al. Gut microbiota-related fitC-peptide production is associated with progression of coreceptor Arirotide activation in HIV-1 infected adults on stable antiretroviral therapy. J Infect Dis 2018;219(8):1474–9.

Palmer CS, Henstridge DC, Yu D, Singh A, Balderson B, Duquette G, et al. Emerging role and characterization of Immunometabolism: relevance to HIV pathogenesis, serious non-AIDS events, and a cure. J Immunol 2016;199(5):4457–64.

Lofthus BM, Finlay BB. Gut immunometabolism: cellular metabolism turns immune regulation. J Biol Chem 2016;291(1):1–10.

Anzinger JJ, Butter C, Aounallah M, Dagenais-Lussier X, El-Far M, Mehraj V, Jenabian MA, Routy JP, et al. Variations in gut microbiota from ART-treated HIV-1-positive patients. J Infect Dis 2014;210(1):201–5.

Ramendra R, Isnard S, Mehrjah V, Chen J, Zhang Y, Finkelstein M, et al. Circulating LPS and (1–3)-beta-D-Glucan: A Fole a Deux contributing to HIV-associated immune activation. Front Immunol 2019;10:465.

Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, et al. Circulating LPS and (1–3)-beta-D-Glucan is associated with immune activation during HIV infection. J Infect Dis 2019;201(8):1255.

Dominguez-Andres J, Arts RW, Ter Horst G, Greenstein MS, Smeenk SP, Ratter J, et al. Rewiring monocyte glucose metabolism via c-TYPE lectin signaling protects against disseminated intravascular coagulation. Blood 2004;103(15):5258–53.

Tintari C, Merlini E, Braidotti P, Ancona G, Savi F, Tosi D, et al. Impaired gut junctional complex features late-tREATED individuals with subclinical CD4+ T-cell re- gression upon virologically stable combination antiretroviral therapy. AIDS 2016;30(7):991–1003.

Buccigrossi V, Laudiego G, Nicastro E, Miele E, Esposito F, Guarino A. The HIV-1 transactivator factor (tat) induces enterocyte apoptosis through a redox- mediated mechanism. PLoS One 2016;11(12):e016435.

Brenchley JM, Douek DC. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008;1(1):23–30.

Maingat F, Halloran B, Ajarache S, van Marle G, Church D, Gill MJ, et al. Inflammation and epithelial cell function in asymptomatic HIV-1 infection: involvement of endoplasmic reticulum stress. FASEB J 2011;25(7):2211–20.

Kannmoge GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 2007;27(1):123–34.

Cassol E, Rosovour T, Maloff S, Mahaska P, Slavik T, Seeberg C, et al. CD14(+) macrophages that accumulate in the colon of African AIDS patients express pro-inflammatory cytokines and are responsive to lipopolysaccharide. BMC Infect Dis 2015;15:430.

Luo A, Leach ST, Barnes R, Hesson LB, Grimm MC, Simar D. The microbiota and epi-genetic regulation of T helper 17/regulatory T cells: in search of a balanced immune state. Front Immunol 2016;7:417.

Inoue T, Tsuzuki Y, Matsuzaki K, Matsunaga H, Miyazaki J, Hokari R, et al. Blockade of NK cell activation by normal bacteria and bacterial products: implications for allogeneic immune activation during HIV infection. J Immunol 2013;191(5):2164–73.

El Hed A, Khaitan A, Kozhaya L, Manel N, Daikakis D, Borkowski W, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2010;201(6):943–54.

Owaga E, Hsieh RH, mugendi B, Masuku S, Shih CK, Chang JS, Th17 cells as potential probiotic therapeutic targets in inflammatory bowel diseases. Int J Mol Sci 2015;16(9):20841–58.

Wang X, Quinn PJ. Endotoxins: structure, function and recognition. Springer Science & Business Media; 2010.

Smith PD, Smythies LE, Shen R, Greenwell-Wild T, Gliozzi M, Wahl SM. Intestinal microbiota and response to microbial enlocchment. Mucosal Immunol 2011;4(1):31–42.

Kim CJ, McKinnon LR, Kovacs C, Kandel G, Huber S, Chege D, et al. Microbial Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol 2013;191(5):2164–73.

Hao A, Khaotan A, Kozhaya L, Manel N, Daisalakis D, Borkowski W, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2010;201(6):943–54.
Castellano P, Prevedel L, Valdebenito S, Eugenin EA. HIV infection and latency in pediatric Crohn’s disease and murine colitis. In: Pediatric Crohn’s Disease and Murine Colitis. 2013;140(1):87–90.

Dhein J, Taylor KD, Blix J, Silverberg MS, Daly MJ, et al. A genomewide association study identifies IL23R as an inflammatory bowel disease gene. Sci 2006;314(5804):1461–3.

Epel K, Schneider T, Troeger H, Kunzel D, Allers K, Moos V, et al. Impairment of the inflammatory beta-2-adrenergic receptor in untreated but absent in suppressively treated HIV-infected patients. Gut 2009;58(2):220–7.

Guo Q, Liu Q, Wu X, Gao J, Wang Y, Li X, et al. Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected patients. J Infect Dis 2014;209(5):739–48.

Sankaran S, George MD, Reza E, Guadalupes F, Flamm J, Prindiville T, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol 2008;82(11):5384–45.

Walker MA, Rodriguez CA, Yin L, Saporta S, Chinranapisit S, Hsu W, et al. Microbial translocation induces persistent macrophage activation and correlates with immune activation and increased levels of LPS. Curr HIV Res 2011;9(3):148–55.

Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage lipid translocation is associated with increased monocyte activation and dementia in AIDs patients. PLoS One 2008;3(6):e2516.

Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1395–7.

Wallent MA, Rodriguez CA, Yin L, Saporta S, Chinranapisit S, Hsu W, et al. Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy. AIDS 2010;24(9):1281–90.

Egeler RM, Stubblefield Park SR, Sun HC, Hardy G, Clagett B, Ignatz-Hoover J, et al. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013;140(1):87–97.

Pasternak BA, D’Mello S, Jurickova IL, Han X, Willson T, Flick L, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn’s disease and mural inflammatory. Curr HIV Res 2010;16(10):856–69.

Chatterjee MA, Latachik N, Quinn J, Winter ME, Buckhead 3R, Blankson JN, et al. Inflammation in the monocytes and macrophages via endosomal toll-like receptors without induction of type 1 interferon. PLoS Pathog 2010;6(10):e1001048.

Hernandez JC, Lutz E, Urcuqui-Inchima S, de Ettorre G, Paiardini M, Zafar MM. Inflammatory bowel disease: communica- tion between immune and epithelial cells and its therapeutic implications. Front Immunol 2015;6:1.

Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, et al. Simian immunodeficiency virus–induced mucosal interleukin-17 deficiency promotes pathogenesis of Simian Salmonella dissemination from the gut. J Virol 2008;82(4):1973–91.

Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014;20(12):3255–64.

Geremia A, Bianchieri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014;13(1):1–10.

Wolff K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al. IL-12 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic virulence factor in Crohn’s disease. J Immunol 2007;179(5):2973–81.

Dillon SM, Lee EE, Kottner CV, Austin G, Dong Z, Hecht DK, et al. An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic inflammation and endotoxemia. Mucosal Immunol 2014;7(4):983–94.

Funderburg NT, Stubblefield Park SR, Sun HC, Hardy G, Clagett B, Ignatz-Hoover J, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn’s disease and mural inflammatory. Curr HIV Res 2010;16(10):856–69.

Millet F, Vachharajani V, McPhail L, Yuza B, McCauley CE. GAPDH binding to TNF-alpha mRNA contributes to posttranscriptional repression in monocytes: a novel mecha- nism of communication between inflammation and metabolism. J Immunol 2016;196(6):2541–51.

Shehata HM, Murphy AJ, Lee MKS, Gardiner CM, Crowe SM, Sanjabi S, et al. Sugar or fat? metabolic requirements for immunity to viral infections. Front Immunol 2017;8:1131.

Palmer CS, Ostorowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol 2015;6(1):1.

Huang M, DCi D, Smith MI, MacCrowell CL, Mauro C. Immediate-early genes of metabolism: from bystanders to signaling molecules. Trends Biochem Sci 2016;41(5):460–71.

O’Neill LA, Kishotn JB, Rathmell J. A guide to immunometabolism for immuno- logists. Front Immunol 2016;7(1):65; doi:10.3389/fimmu.2016.00655.

Kuzumaki M, Shinomiya H, Shimizu Y, Ohishi K, Utsumi S. Endotoxin-induced en- hancement of glucose influx into murine peritoneal macrophages via GLUT1. Infect Immun 2002;70(7):3190–7.

Freeman AJ, Johnson AR, Sacks GN, Milner J, Kirk EL, Troester MA, et al. Meta- bolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem 2014;289(11):7884–96.

Kolly B, O’Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res 2015;25(7):771–84.

Cameron AM, Castoldi A, Sanin DE, Flachsmann LJ, Field CS, Puleston DJ, et al. Inflammation and decreased glucose metabolism in CD4+ T cells and monocytes: new perspectives in HIV pathogenesis. EBioMedicine 2016;19(3):309–19. https://doi.org/10.1016/j.ebiom.2015.12.007.

Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. Oxidative metabolism and PGC-1b enhances metabolic macrophage-mediated inflammation. Cell Metab 2016;4(1):13–24.

Venter G, Gerleman FT, Wijers M, Willemse M, Frans J, Wiersinga B. Glucose controls morphodynamics of LPS-stimulated macrophages. PLoS One 2014;9(5):e96786.

Geniets V, Macintyre A, Nichols A, Rathmell J. Glucose metabolism in CD4+ T cells sustains modulatory disease and autoimmune (P4126). J Immunol 2013;190(Supplement 1):1919.

Parada Venegas D, De la Fuente MR, Landskron G, Gonzalez MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regula- tion and its relevance for inflammatory bowel diseases. Front Immunol 2015;6:277.

Thibault R, Blachier F, Darcy-Villarin B, de Cocket P, Bourrellie A, Seguin JP. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport de- pendency. Infect Immun 2010;78(4):3848–55.

Palmer CS, Anzingger JJ, Zhou J, Gouillou M, Landay A, Jaworowski A, et al. Glucose transporter 1-expressing Proinflammatory monocytes are elevated in combination antiretroviral therapy-treated and untreated HIV+ subjects. J Immunol 2014;193 (11):5595–603.

Palmer CS, Palchauhuri AR, Albargh A, Abdel-Mohsen M, Crowe SM. Exploiting immune cell metabolic machinery for functional HIV cure and the prevention of inflammation. Front Immunol 2010;16(4):3848–55.

Butterfield TR, Hansa DB, Kaplan RC, Kizer JR, Dunkin HG, Young MA, et al. In- creased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease. AIDS 2017;31(2):195–205.

Palmer CS, Cherry CL, Sada-Ovalle I, Singh A, Crowe SM. Glucose metabolism in T cells and monocytes: new perspectives in HIV pathogenesis. EBioMedicine 2016;3:631–41.

Platas D, Routy JP, Ancuta P. New Th17-specific therapeutic strategies for HIV re- mission. Curr Opin HIV AIDS 2019;14(2):85–92.

Belizario JF, Faintuch J, Garay-Malpartida M. Gut microbiome Dysbiosis and Immunometabolism: new Frontiers for treatment of metabolic diseases. Mediators Inflamm 2018;2018:2037838.

Vijayan V, Pradhan P, Braud L, Fuchs HR, Guer E, Motterlini R, et al. Human and murine macrophages exhibit differential metabolic responses to lipopolysacchar- ide – a divergent role for glycosylation. Redox Biol 2019;22:101147.
Datta PK, Deshmane S, Khalili K, Merali S, Gordon JC, Fecchio C, et al. Glutamate metabolism in HIV-1 infected macrophages: role of HIV-1 Vpr. Cell Cycle 2016;15(17):2288–98.

Low H, Cheng L, Di Yacovo MS, Churchill MJ, Meikle P, Bukrinsky M, et al. Lipid metabolism in patients infected with Nef-deficient HIV-1 strain. Atherosclerosis 2016;244:22–8.

Ahmed D, Cassol E. Role of cellular metabolism in regulating type I interferon responses: implications for tumour immunology and treatment. Cancer Lett 2017;409:20–9.

Wang F, Zhang S, Jeon R, Vuckovic I, Jiang X, Lerman A, et al. Interferon gamma induces reversible metabolic reprogramming of M1 macrophages to sustain cell viability and pro-inflammatory activity. EBioMedicine 2018;30:303–16.

Maidji E, Somsouk M, Rivera JM, Hunt PW, Stoddart CA. Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog 2017;13(2):e1006202.

Tarancon-Diez L, Rodriguez-Gallego E, Rull A, Peraire J, Vilades C, Portilla I, et al. Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection. EBioMedicine 2019;42:86–96.

Ricciardi S, Manfrini N, Affleri R, Calamita P, Crosti MC, Gallo S, et al. The translational machinery of Human CD4(+) T Cells Is Paced for activation and controls the switch from quiescence to Metabolic Remodeling. Cell Metab 2018;28(6):895–906 [e5].

Valle-Casuso JC, Angin M, Volant S, Passaes C, Monceaux V, Mikhailova A, et al. Cellular metabolism is a major determinant of HIV-1 Reservoir Seeding in CD4(+) T Cells and Offers an Opportunity to Tackle Infection. Cell Metab 2019;29(3):611–26 [e5].

Pallett LJ, Schmidt N, Schurich A. T cell metabolism in chronic viral infection. Clin Exp Immunol 2019.

Routy JP, Isoard S, Mehraj V, Ostrowski M, Chornont N, Ancuta P, et al. Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised lilac pilot study protocol. BMJ Open 2019;9(4):e028444.

O’Sullivan D, Sanin DE, Pearce EJ, Pearce EL. Metabolic interventions in the immune response to cancer. Nat Rev Immunol 2019;19(5):324–35.

Kessing CF, Nixon CC, Li C, Tsai P, Takata H, Mousseau G, et al. In vivo suppression of HIV rebound by Didexhydro-Cortistatin a, a "block-and-lock" strategy for HIV-1 treatment. Cell Rep 2017;21(3):600–11.

Besnard E, Hakre S, Kampmann M, Lim HW, Hosmane NN, Martin A, et al. The mTOR complex controls HIV latency. Cell Host Microbe 2016;20(6):785–97.

Clerc I E, Abba Moussa D S, Vahlas Z M, Tardito S HW, Oburoglu L NN, Hope TJ A, et al. Entry of glucose- and glutamine-derived carbons into the citric acid cycle supports early steps of HIV-1 infection in CD4 T cells. Nat Metab 2019;1(7):717–30.
Author/s:
Alzahrani, J; Hussain, T; Simar, D; Palchaudhuri, R; Abdel-Mohsen, M; Crowe, SM; Mbogo, GW; Palmer, CS

Title:
Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities

Date:
2019-08-01

Citation:
Alzahrani, J., Hussain, T., Simar, D., Palchaudhuri, R., Abdel-Mohsen, M., Crowe, S. M., Mbogo, G. W. & Palmer, C. S. (2019). Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities. EBIOMEDICINE, 46, pp.522-531. https://doi.org/10.1016/j.ebiom.2019.07.027.

Persistent Link:
http://hdl.handle.net/11343/249609

File Description:
published version

License:
CC BY-NC-ND